Save time and get answers to complex questions with AI chat
Pramlintide acetate price?Does lipitor's effectiveness decrease with high fat meals?Somatuline depot patent expiry date?Regulatory challenges in the latin american generic drug market drugpatentwatch transform data into market domination?Mebendazole ingredients?
See the DrugPatentWatch profile for Xofluza
The tablet size of Xofluza (baloxavir marboxil) is not publicly disclosed by its manufacturer, Shionogi, or through regulatory filings. Information regarding the physical dimensions of Xofluza tablets is not readily available.
Xofluza is administered orally as a single dose [1]. It is available in two dosage strengths: 20 mg and 40 mg tablets [2].
Xofluza is an antiviral medication used for the treatment of acute uncomplicated influenza (flu) in patients 12 years of age and older who have been symptomatic for no more than 48 hours [1]. It is also used for post-exposure prophylaxis of influenza in individuals 12 years of age and older [2].
Xofluza was developed by Shionogi & Co., Ltd. [1]. Roche holds the marketing and distribution rights in countries outside of Japan and Taiwan [3].
Xofluza targets the influenza virus's cap-dependent endonuclease, an enzyme essential for viral replication [1]. By inhibiting this enzyme, Xofluza blocks viral DNA replication and transcription [2]. This mechanism is different from neuraminidase inhibitors, which are another class of influenza medications [1].
Other Questions About Xofluza :